BCL2L1 and neoplasm: DT2216, a first-in-class selective BCL-XL degrader, is reported to target tumor cells more selectively as it targets BCL-XL to the Von Hippel-Lindau (VHL) E3 ligase for proteasomal degradation; platelets have minimal expression of VHL [47,49].